| Literature DB >> 35262626 |
Marco Luciani1,2, Francesca Gatto1, Monah Abou Alezz1, Anna Maria Sole Giordano1,2, Chiara Beghè3, Lucrezia Della Volpe1,2, Alessandro Migliara1,2, Sara Valsoni1, Marco Genua1, Monika Dzieciatkowska4, Giacomo Frati1, Julie Tahraoui-Bories1, Silvia Clara Giliani5, Simona Orcesi6,7, Elisa Fazzi8, Renato Ostuni1, Angelo D'Alessandro4, Raffaella Di Micco1, Ivan Merelli1, Angelo Lombardo1, Martin A M Reijns9, Natalia Gromak3, Angela Gritti1, Anna Kajaste-Rudnitski1.
Abstract
Aberrant induction of type I IFN is a hallmark of the inherited encephalopathy Aicardi-Goutières syndrome (AGS), but the mechanisms triggering disease in the human central nervous system (CNS) remain elusive. Here, we generated human models of AGS using genetically modified and patient-derived pluripotent stem cells harboring TREX1 or RNASEH2B loss-of-function alleles. Genome-wide transcriptomic analysis reveals that spontaneous proinflammatory activation in AGS astrocytes initiates signaling cascades impacting multiple CNS cell subsets analyzed at the single-cell level. We identify accumulating DNA damage, with elevated R-loop and micronuclei formation, as a driver of STING- and NLRP3-related inflammatory responses leading to the secretion of neurotoxic mediators. Importantly, pharmacological inhibition of proapoptotic or inflammatory cascades in AGS astrocytes prevents neurotoxicity without apparent impact on their increased type I IFN responses. Together, our work identifies DNA damage as a major driver of neurotoxic inflammation in AGS astrocytes, suggests a role for AGS gene products in R-loop homeostasis, and identifies common denominators of disease that can be targeted to prevent astrocyte-mediated neurotoxicity in AGS.Entities:
Mesh:
Year: 2022 PMID: 35262626 PMCID: PMC8916121 DOI: 10.1084/jem.20211121
Source DB: PubMed Journal: J Exp Med ISSN: 0022-1007 Impact factor: 14.307